<DOC>
	<DOCNO>NCT00309725</DOCNO>
	<brief_summary>The objective trial investigate effect galantamine ( acetylcholinesterase inhibitor ) heart rate PR interval ( time take heart 's electrical impulse get atrium ventricle ) administration rapidly increase dos end 2-week treatment period 32 mg per day patient Alzheimer 's disease .</brief_summary>
	<brief_title>A Cardiac Safety Study Galantamine Treatment Alzheimer 's Disease .</brief_title>
	<detailed_description>This 6-week , double-blind , parallel group trial also design detect cardiac arrhythmia conduction disturbance , heart block . Holter monitor Electrocardiograms use measure cardiac parameter baseline , end Week 2 ( first dose 12 mg twice daily ) , end Week 4 ( first dose 16 mg twice daily ) Week 6 ( 2 week maximum tolerate dose allow trial , i.e. , 24 32 mg/day ) . Other safety data collect adverse event report , urine blood analysis , vital sign physical examination . Drug level blood also test . Patients randomize receive either placebo galantamine 32 mg daily ( i.e. , 4 mg twice daily Week 1 , 8 mg twice daily Week 2 , 12 mg twice daily Weeks 3 4 , 16 mg twice daily Weeks 5 6 ) . Dosage could reduce 16 mg twice daily 12 mg twice daily first 3 day 32 mg/day dose period , patient could tolerate high dose . This titration rapid dose higher currently recommend treatment .</detailed_description>
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Galantamine</mesh_term>
	<criteria>Outpatients diagnose Alzheimer 's disease accordance NINCDSADRDA ( National Institute Neurological Communicative Diseases Stroke/Alzheimer 's Disease Related Disorders Association ) classification probable Alzheimer 's disease Mild/moderate dementia evidence MiniMental State Examination ( MMSE ) score range 11 24 , inclusive , baseline History cognitive decline gradual onset progressive period least 6 month Evidence sustain memory deterioration otherwise alert patient , plus additional impairment least one five area : orientation , judgment problemsolving , function community affair , function home hobby , function personal care Patients live regular daily visit one responsible caregiver capable assist patient 's medication , able accompany patient assessment , willing provide information patient.On day patient send home Holter monitor , caregiver require stay patient household 24 hour duration cardiac assessment ensure monitor lead placement remain intact . The caregiver available following day return Holter monitor device Patient patient 's relative , guardian legal representative sign informed consent . Disorders Parkinson 's disease , Pick 's disease , Huntington 's chorea , Down 's syndrome , CreutzfeldtJakob disease , Cushing 's syndrome , uncontrolled diabetes Cognitive impairment result trauma , injury , hypoxia Infection Mental retardation dementia clinically active cerebrovascular disease Current , clinically significant cardiovascular disease would limit patient 's ability complete sixweek trial .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2011</verification_date>
	<keyword>Alzheimer 's Disease</keyword>
	<keyword>cardiac arrhythmia</keyword>
</DOC>